arrow_back Back to App

More Research on Pediatric Cancer Drugs

This act aims to accelerate research into new cancer drugs, especially molecularly targeted ones, for children. This could give children with cancer faster access to innovative therapies, increasing their chances of recovery and improving their quality of life. Pharmaceutical companies will be required to conduct studies on the use of adult cancer drugs in children.
Key points
Increased focus on research into pediatric cancer drugs, including molecularly targeted therapies.
Requirement for clinical and preclinical studies of cancer drugs in children to ensure appropriate dosing and safety.
Possibility of testing drugs in combination with other substances, potentially increasing treatment effectiveness.
Accelerated access for children to modern cancer therapies.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_4215
Sponsor: Sen. Rubio, Marco [R-FL]
Process start date: 2022-05-12
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Give Kids a Chance Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_4215.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2022-05-12.

What are the main provisions?

Key points include:

  • Increased focus on research into pediatric cancer drugs, including molecularly targeted therapies.
  • Requirement for clinical and preclinical studies of cancer drugs in children to ensure appropriate dosing and safety.
  • Possibility of testing drugs in combination with other substances, potentially increasing treatment effectiveness.
  • Accelerated access for children to modern cancer therapies.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Rubio, Marco [R-FL].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health